Incidence and risk factors for venous thromboembolism;Épidémiologic et facteurs de risque de la maladie thrombo-embolique veineuse

Revue du Praticien

Volumn 57, Issue 7, 2007, Pages

  Oger, Emmanuel ^b   Mottier, Dominique ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S; PROTHROMBIN; ANTICOAGULANT AGENT; ORAL CONTRACEPTIVE AGENT;

CAUCASIAN; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; HOSPITALIZATION; HUMAN; INCIDENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; ADULT; AGE; AGED; ARTICLE; BLOOD; ESTROGEN THERAPY; FEMALE; FRANCE; GENETICS; MALE; MUTATION; NEOPLASM; PARALYSIS; PREGNANCY; STATISTICS; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MUTATION; NEOPLASMS; PARALYSIS; PREGNANCY; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34248581285     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004;140:330-7.
2. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-9.
3. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBO Study Group. Groupe d'etude de la thrombose de Bretagne occidentale. Thromb Haemost 2000;83:657-60.
4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
5. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
6. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.
7. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:117-121.
8. Noboa S, Mottier D, Oger E. Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. J Thromb Haemost 2006;4:2720-2.
9. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96.
10. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
11. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999;14:55-61.
12. Scarabin PY, Oger E, Plu-Bureau G. Estrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
13. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779-83.
14. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
15. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
17. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-16.
18. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9.
19. Oger E, Lacut K, Le Gal G, et al. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 2006;4:793-9.
20. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. Circulation 2001;104:2442-6.
21. Den Heijer M, Willems HP, Blom HJ et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007;109:139-44.
22. Couturaud F, Kearon C, Leroyer C, et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 2006;96:744-9.
23. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500.